Over the last decade the number of clinical trials involving recombinant Adeno-Associated Viral (rAAV) vectors has dramatically increased. Currently, ~80% of the trials ongoing for gene therapy involve AAV vectors. Directly related to this exponential growth, the diversity of serotypes has expanded and the demand for larger quantities of highly purified material, manufactured to cGMP standards, increases each day.
For Contract Development and Manufacturing companies (CDMO) like YposKesi, the manufacturing challenges are centred around flexibility, robustness and productivity, especially with regards to purification. In other words, it is critical for such companies to have universal tools available to address any serotype with minimal process adjustments, ensuring consistent process performance and available in formats allowing for a reduction in operating times and costs.
In this webinar, discover how POROS™ CaptureSelect™ AAVX resin can be used as a pan-affinity tool for the universal capture of AAV vectors, and how YposKesi optimized the operational parameters to make the resin an efficient, robust and productive purification platform that fits with CDMOs’ constraints.